What is Ocean Biomedical, Inc. (OCEAW)?

Ocean Biomedical, Inc. (OCEAW) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of OCEAW?

The current price of OCEAW is $0.03. Prices are updated in real time on Stocks360.

What is OCEAW's price-to-earnings (PE) ratio?

OCEAW's trailing twelve-month PE ratio is -0.09, based on current price and earnings per share data available on Stocks360.

What is OCEAW's market capitalization?

OCEAW's market capitalization is $20,396,136.00, placing it in the small-cap tier.

Ocean Biomedical, Inc. (OCEAW)

Stock analysis · NASDAQ · Healthcare · Biotechnology

$0.03

Market Cap

$20.40M

PE (TTM)

-0.09

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

0.73

Day Range

$0.00 – $0.03

52-wk Range

$0.00 – $0.03

Avg Volume

N/A

Volume

184.70K

Ocean Biomedical, Inc. (OCEAW) is a publicly traded company in the Healthcare sector. Latest price: $0.03. Market cap $20.40M. Trailing PE -0.09. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

You have viewed 7 SEO analysis pages

Unlock saved watchlists, personalized setups, and referral credits with a free Stocks360 account.

Continue with free signup

1-Year Price

2025-11-25 · $0.03 2026-02-10 · $0.03 (+0.00%)

Proprietary Signals

Signal snapshot temporarily unavailable.

About Ocean Biomedical, Inc.

Ocean Biomedical, Inc. is a biopharmaceutical enterprise primarily engaged in identifying and advancing novel therapeutic agents. Their research and development efforts span several key disease areas, including cancer, fibrotic conditions, infectious illnesses, and inflammatory disorders. The company's current development pipeline features both mono-specific and bi-specific humanized monoclonal antibodies (mAbs). These candidates are engineered to target Chi3l1 and are being investigated for treating non-small cell lung cancer and glioblastoma multiforme, a type of brain tumor. Furthermore, Ocean Biomedical is progressing a small molecule therapeutic designed to interact with Chit1, intended for individuals afflicted with Idiopathic Pulmonary Fibrosis and Hermansky-Pudlak Syndrome. Their proprietary WPDS platform has generated three additional product candidates: a vaccine aimed at preventing malaria; a humanized monoclonal antibody treatment; and a small molecule treatment, with both malaria therapeutics specifically targeting the Plasmodium falciparum glutamic-acid-rich protein (PfGARP). The company is also developing a therapy for hospitalized patients suffering from COVID-19.…

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-0.09×
P/S (TTM)	0.00×
P/B	-0.01×
PEG	0.02×
P/FCF (TTM)	-4.88×
EV / EBITDA	0.00×
EV / Sales	0.00×
Earnings Yield	-402.77%
Free Cash Flow Yield	-20.49%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$36.70M
Net Income (TTM)	-$82.15M
Free Cash Flow (TTM)	-$6.23M
Net Debt	$16.30M
Working Capital	-$33.08M
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Return on Equity	3.50%
Return on Invested Capital	0.00%